Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Matthew D. Hellmann, Luis Paz‐Ares, Bogdan Żurawski et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Medicine, Neurology, Oncology +14

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Sarah B. Goldberg, Scott Gettinger, Amit Mahajan et al. · The Lancet Oncology · 2016 · 996 citations · Full text

Medicine, Oncology, Pharmacology +16